ELV monthly performance report
Monthly ELV research: returns, drawdown, relative strength, seasonality, and key stats.
ELV monthly report
—
Key takeaways
- Elevance Health (ELV) closed August 2026 at $391.24, up 4.10% for the month and +41.54% over the trailing 12 months.
- Year-to-date, ELV is +11.61%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +11.65% versus its 200-day moving average ($350.42), a bullish technical signal.
- Over the past three years, ELV has underperformed the S&P 500 by −87.82%, with a relative strength index reading of 48.7.
- Win rate over the trailing 39 months stands at 53.8% — 21 positive months versus 18 negative months.
Elevance Health ended August 2026 at $391.24, posting a monthly return of +4.10%. The S&P 500 returned +3.05% over the same window, leaving relative performance at +1.05%.
The current quarter stands at −1.02% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +11.65% versus the 200-day moving average ($350.42).
Year-to-date, ELV is +11.61% against SPY +12.89%, a gap of −1.28%. The stock is currently −9.93% below its 52-week high, with maximum 3-year drawdown at −51.15%.
| Period | ELV | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +3.50% | −0.20% | +3.70% |
| 1 Week | +1.43% | +3.90% | −2.48% |
| 1 Month | +4.10% | +3.05% | +1.05% |
| 3 Months | +3.88% | +7.11% | −3.24% |
| 6 Months |